Introduction
Classically, HIV-associated nephropathy (HIVAN) is diagnosed in the setting of virologically uncontrolled infection. However, HIVAN can occur in some cases with undetectable HIV-1 RNA levels [1] . Our working hypothesis was that intracellular HIV-1 proviral DNA load can be used as a marker in this particular patient population.
Indeed, recent studies have shown that peripheral blood mononuclear cell (PBMC) HIV-1 DNA load is an independent predictor of both progression of disease after a primary HIV type 1 infection and response to treatment with highly active anti-retroviral therapy (HAART) [2] . Furthermore, Hatzakis et al. demonstrated that cellular HIV-1 DNA load predicts HIV RNA rebound and the outcome of HAART [3] . While its use has not yet been incorporated into clinical practice, perhaps due to the lack of standardization of polymerase chain reaction (PCR) measurements, HIV-1 DNA quantification in PBMCs may play a role in the management of HIV-1-infected individuals in the future [4] . Given its utility as a clinical marker in the progression of HIV-1 disease, there may be a role for its use as a predictive marker for HIV-associated nephropathy (HIVAN), an aggressive renal disease that typically presents with high-grade proteinuria and rapid decline in renal function. Definitive diagnosis requires kidney biopsy as none of the clinical criteria is pathognomonic of the diagnosis. Animal models of HIVAN suggest that expression of HIV-1 envelope proteins in renal epithelial cells is central to HIVAN pathogenesis [5] . This study investigates whether the PBMC HIV-1 proviral DNA load may be used as a predictive marker for the development of HIVAN, especially in patients whose RNA viral load is undetectable.
Materials and methods

Patients and clinical samples
This prospective study was conducted between January 2005 and December 2009, in the Department of Nephrology at Pitie-Salpetiere Hospital in Paris, France. One hundred HIV-1 patients' whole blood samples were taken from HIV-1-seropositive patients over the age of 18, both on and off HAART who were admitted for a kidney biopsy related to renal abnormalities defined as having renal insufficiency (creatinine clearance >60 mL/min/1.73 m 2 ), nephrotic syndrome, proteinuria, microscopic haematuria, and/or sterile pyuria. Both blood and tissue samples were obtained simultaneously. Biopsies were interpreted by a single blinded pathologist. Informed written consent to perform the additional viro-logical tests on tissue samples was obtained from all individuals enrolled in the study.
Virological parameters Plasma HIV-1 RNA quantification. In plasma, HIV-1 RNA was measured using the Amplicor HIV-1 Monitor 1.5 Test (Roche Diagnostic Systems, Neuilly sur Seine, France) according to the manufacturer's instructions and with a limit of quantification of 40 copies/mL.
Quantification of HIV-1 proviral DNA in PBMCs and kidney biopsies for HIV-1 DNA. Renal tissue of each biopsy was analysed for the presence of HIV-1 proviral DNA. Total cell DNA was extracted from PBMCs and kidney biopsy by adsorption on silica membranes (QIAamp Tissue Extraction Kit, DNA Blood Mini Kit for the PBMCs and DNA Mini Kit for renal tissue, Qiagen, Hilden, Germany). HIV-1 proviral DNA was quantified in duplicate by real-time PCR. TaqMan Exogenous Internal Positive Control (IPC Kit; AB Applied Biosystems, Foster City, CA, USA), a pre-optimized internal control, was added to each sample to allow detection of PCR inhibitors. The amplification was performed and analysed with an ABI Prism 7000 Sequence Detector System (AB Applied Biosystems). To normalize sample-to-sample variations in terms of cell count and yield of DNA extraction, we determined the number of cells extracted by quantifying the number of copies of albumin gene in 10 mL of extracted DNA. The PCR primers for HIV-1 DNA and albumin gene quantifications have been described elsewhere [6, 7] . Results were expressed as HIV-1 DNA copies per 1.5 × 10 5 cells with a PCR limit of detection of five HIV-1 DNA copies.
Statistical analyses
The participants' demographic and clinical characteristics were compared by HIVAN status using the Mann-Whitney U-test for continuous and the Fisher's exact test for categorical data. Operating characteristics of plasma RNA viral load, proviral DNA, CD4 count and nephrotic-range proteinuria in the diagnosis of HIVAN at different cut-off levels were determined using the biopsy pathologic report as the criterion standard. A similar analysis restricted to participants of black race was also performed. The relationship between PBMC HIV-1 proviral DNA and kidney proviral DNA, plasma HIV RNA, and CD4 count was calculated using the Spearman rank correlation. All analyses were conducted using STATA statistical software (version 10.0; Stata Corporation, College Station, TX, USA). All tests of significance were two-tailed (α = 0.05).
Results
Our study included 100 patients with the diagnosis of HIV and kidney dysfunction. The median age of our study group was 45, with a majority being black males. The median CD4 count was 299, with half of the patients with undetectable viral loads; the median creatinine was 1.75, and the median level of proteinuria was 1.25 g/dL. Of the 100 patients, 25 had biopsy-proven HIVAN. As shown in Table 1 , patients with HIVAN were younger, were of black race and had more severe kidney disease at the time of renal biopsy. As for the other 75 patients, 20%, 24%, 25.33% and 30.66% had nephroangiosclerosis, acute tubular necrosis, acute interstitial nephritis and various glomerulopathies, respectively. In addition, HIV-1 infection was more advanced in those with HIVAN compared with those without. These patients had a lower median CD4 count and higher median plasma RNA viral load compared with those without HIVAN. Among those patients with HIVAN, seven patients had detectable PBMC HIV-1 proviral DNA load despite undetectable plasma RNA viral load. Renal tissue proviral DNA was detectable in all 25 patients with HIVAN. Applying different cut-off levels of selected clinical biomarkers (Table 2) revealed that a PBMC HIV-1 proviral DNA of <10 copies/10 5 PBMCs was 100% sensitive for the diagnosis of HIVAN with a negative predictive value of 100%. Conversely, proviral DNA load had poor specificity and positive predictive value (29% and 32%, respectively). Analyses restricted to black participants yielded similar results. A PBMC HIV-1 proviral DNA load of <10 copies/mL remained the best biomarker to exclude the diagnosis of HIVAN compared with plasma viral RNA, CD4 counts and nephrotic-range proteinuria. 
Discussion
This is the first study to evaluate the role of PBMC HIV-1 proviral DNA as a potential clinical predictive marker for HIVAN. Though this is demonstrated in a relatively small sample size, undetected PBMC HIV-1 proviral DNA <10 copies/mL demonstrated a 100% negative predictive value of HIVAN. The results were unchanged in participants of black race who are at the highest risk for HIVAN. This challenges the current HIV control definition (undetectable HIV RNA and higher CD4) as there is evidence that PBMC HIV-1 proviral DNA levels among patients with undetectable HIV RNA levels on HAART were associated with both (i) a higher CD4 at initiation of HAART and (ii) a longer duration of being treated with HAART [8] . Thus, the low PBMC HIV-1 proviral DNA level appears to be a marker for people who have done well on HAART for a long time-a situation that makes HIVAN very unlikely. Therefore, this marker can be used in conjunction with the clinical picture in the subset of patients who do not have a detectable plasma RNA viral load and in whom a kidney biopsy is unattainable or contraindicated to help in excluding the diagnosis of HIVAN. This said, we are conscious that the proviral DNA level is not linearly related to the development of HIVAN in levels higher than 10 copies/mL. Practically, a patient who has >10 copies/mL proviral DNA cannot have HIVAN, while another with a value >10 copies/mL can have HIVAN or any other nephropathy. It should be noted that since PBMC HIV-1 proviral DNA represents the reservoir of HIV-1 DNA in T cells and it is always 'detectable', using a cut-off of <10 in our study should not merely be interpreted as undetectable proviral load but rather a low reservoir load. Although the quantitative determination of plasma HIV-1 RNA copies directly represents viral replication and is the main prognostic parameter for disease progression [9] , HIV-1 proviral DNA load as a representative of the infection reservoir in PBMC and lymphoid tissues plays a pivotal role in immune surveillance escape [10, 11] . The amount of proviral DNA might also be an important virological marker for exploring viral reservoirs and assessing the impact of suppressive treatment [12] . Moreover, the presence of this reservoir indicates the possibility of a viral replication rebound when therapy is interrupted or discontinued.
Renal proviral DNA was noted to be present in all patients with HIVAN. This result suggests that proviral DNA is required to be incorporated in the kidney to cause HIVAN. This is consistent with other studies demonstrating HIV-1 RNA and DNA in renal epithelial cells in HIV-1-seropositive patients [13, 14] . Moreover, if proviral DNA is required to be incorporated into the specific kidney cells to cause disease, then plasma levels and thus an infection reservoir could also be present to allow for enough viraemia to be present to cause disease as suggested by our data. On the other hand, it is possible that an in situ renal replication becomes a source for viral particle release into circulating PBMCs: it is no longer a passage from blood towards peripheral tissues but in the reverse direction.
The classically associated clinical markers of HIVAN such as black race, low CD4 count and the significant renal disease at presentation were again demonstrated in this study. Of interest, 28% of patients with confirmed HIVAN diagnosis had an undetectable plasma RNA viral load, higher than previously reported [15] . This may potentially take place in patients who have recently started HAART, in as short as 2-4 weeks with modern potent regimens.
Further studies are required to assess whether proviral DNA load levels can be a marker of progression of disease in HIVAN as it has been shown to be in HIV-1 itself.
